

No. 1402

6 October 2003

MEDICAL SCHEMES ACT, 1998 (ACT NO. 131 OF 1998)

REGULATIONS MADE IN TERMS OF THE MEDICAL SCHEMES ACT, 1998


THERAPEUTIC ALGORITHMS FOR CHRONIC CONDITIONS

The Regulations made under the Medical Schemes Act, 1998, published under Government Notice No. R1262 of 20 October 1999, as amended by the following Government Notices: No. R 570 of 5 June 2000; No. R. 650 of 30 June 2000; No. R 247 of 1 March 2002 and No. R 1360 of 4 November 2002, provides, in Annexure A, as follows: "Treatment: diagnosis, medical management and medication, to the extent that this is provided for by way of a therapeutic algorithm for the prescribed condition, published by the Minister in the *Gazette*".

I, ME Tshabalala-Msimang, Minister of Health, hereby issue therapeutic algorithms referred to in Annexure A to the regulations.

THERAPEUTIC ALGORITHMS

ADDISON'S DISEASE



Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

ASTHMA**Diagnosis**

Made on symptoms and signs
Objective measurement:
FEV1 improvement possible $\geq 15\%$
[& 200ml increase after short acting β_2 agonist (400 μ g MDI and spacer)]

Aims of Management:
Control symptoms and prevent exacerbations
Achieve best possible peak flow
Minimise adverse effects

Stepwise Approach:

Start treatment at step most appropriate to initial severity
Achieve early control
Maintain stepping up or stepping down therapy

CLASSIFICATION OF SEVERITY**Management of Chronic Asthma in Adults****Classify Severity at Presentation**

	Intermittent	Persistent		
		Mild	Moderate	Severe
Category	I	II	III	IV
Daytime symptoms	$\leq 2/\text{week}$	2-4/week	> 4/week	Continuous
Night-time symptoms	$\leq 1/\text{month}$	2-4/month	> 4/week	Frequent
PEF (predicted)	$\geq 80\%$	$\geq 80\%$	60-80%	< 60%

START TREATMENT AT MOST APPROPRIATE STEP

Step 1: Mild Intermittent Asthma


Inhaled short acting β_2 agonist as required

Step 2: Mild Persistent Asthma

Reliever: β_2 agonist as required;
Preventer: Add inhaled corticosteroid 400-800 μ g/day
(Equivalent to beclomethasone MDI & spacer)

Step Down

Step Up

**Glossary:**


- FEV1 – Forced expiratory volume in 1 second
- β_2 – Beta-2 receptor
- MDI – Metered dosage inhaler
- PEF – Peak expiratory flow
- LABA – Long acting beta-2 receptor agonist
- SR – Slow release

Applicable ICD 10 Coding:

- J45 Asthma
 - J45.0 Predominantly allergic asthma
 - J45.1 Nonallergic asthma
 - J45.8 Mixed asthma
 - J45.9 Asthma, unspecified
- J46 Status asthmaticus

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

BRONCHIECTASIS**Glossary:**

- COPD – Chronic obstructive pulmonary disease


Applicable ICD 10 Coding:

- J47 Bronchiectasis
- Q33.4 Congenital bronchiectasis

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CARDIAC FAILURE



NOTE: If patient truly intolerant to ACE inhibitor, consider hydralazine & isosorbide dinitrate combination therapy

Glossary:


- *ACE inhibitor* – Angiotensin converting enzyme inhibitor
- Serum K⁺ – Serum potassium
- *β-blocker* – Beta-receptor blocker
- NYHA – New York Heart Association
- LV – Left ventricular

Applicable ICD 10 Coding:

- I50 Heart failure
 - I50.0 Congestive heart failure
 - I50.1 Left ventricular failure
 - I50.9 Heart failure, unspecified
- I11.0 Hypertensive heart disease with (congestive) heart failure
- I13.0 Hypertensive heart and renal disease with (congestive) heart failure
- I13.2 Hypertensive heart and renal disease with both (congestive) heart failure and renal failure

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CARDIOMYOPATHY

NOTE: If patient truly intolerant to ACE inhibitor, consider *hydralazine* & *isosorbide dinitrate* combination therapy

Glossary:


- *ACE inhibitor* – Angiotensin converting enzyme inhibitor
- Serum K⁺ – Serum potassium
- *β -blocker* – Beta-receptor blocker
- NYHA – New York Heart Association
- LV – Left ventricular


Applicable ICD 10 Coding:

- I42 Cardiomyopathy
 - I42.0 Dilated cardiomyopathy
 - I42.1 Obstructive hypertrophic cardiomyopathy
 - I42.2 Other hypertrophic cardiomyopathy
 - I42.3 Endomyocardial (eosinophilic) disease
 - I42.4 Endocardial fibroelastosis
 - I42.5 Other restrictive cardiomyopathy
 - I42.6 Alcoholic cardiomyopathy
 - I42.7 Cardiomyopathy due to drugs and other external agents
 - I42.8 Other cardiomyopathies
 - I42.9 Cardiomyopathy, unspecified
- I25.5 Ischaemic cardiomyopathy

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CHRONIC RENAL DISEASE



Severe Chronic Renal Failure (Cr > 400 μmol/l)

Patients require early nephrological referral for management and assessment for dialysis and transplant

Glossary:

- ACE inhibitor – Angiotensin converting enzyme inhibitor
- Serum Na⁺ – Serum sodium
- β-blocker – Beta-receptor blocker
- BP – Blood pressure
- Hb – Haemoglobin
- Cr/Serum Cr – Serum creatinine
- Serum Ca⁺⁺ – Serum calcium
- 1α-hydroxy – 1-alpha-hydroxy
- PO⁴ – Phosphate

Applicable ICD 10 Coding:


- N03 Chronic nephritic syndrome
 - N03.0 Chronic nephritic syndrome, minor glomerular abnormality
 - N03.1 Chronic nephritic syndrome, focal and segmental glomerular lesions
 - N03.2 Chronic nephritic syndrome, diffuse membranous glomerulonephritis

Applicable ICD 10 Coding: (continued)

- N03.3 Chronic nephritic syndrome, diffuse mesangial proliferative glomerulonephritis
- N03.4 Chronic nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis
- N03.5 Chronic nephritic syndrome, diffuse mesangiocapillary glomerulonephritis
- N03.6 Chronic nephritic syndrome, dense deposit disease
- N03.7 Chronic nephritic syndrome, diffuse crescentic glomerulonephritis
- N03.8 Chronic nephritic syndrome, other
- N03.9 Chronic nephritic syndrome, unspecified
- N11 Chronic tubulo-interstitial nephritis
 - N11.0 Nonobstructive reflux-associated chronic pyelonephritis
 - N11.1 Chronic obstructive pyelonephritis
 - N11.8 Other chronic tubulo-interstitial nephritis
 - N11.9 Chronic tubulo-interstitial nephritis, unspecified
- N18 Chronic renal failure
 - N18.0 End-stage renal disease
 - N18.8 Other chronic renal failure
 - N18.9 Chronic renal failure, unspecified
- I12.0 Hypertensive renal disease with renal failure
- I13.2 Hypertensive heart and renal disease with both (congestive) heart failure and renal failure
- O10.2 Pre-existing hypertensive renal disease complicating pregnancy, childbirth and the puerperium
- O10.3 Pre-existing hypertensive heart and renal disease complicating pregnancy, childbirth and the puerperium

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Glossary:


- FEV1 – Forced expiratory volume in 1 second
- β_2 – Beta-2 receptor

Applicable ICD 10 Coding:

- J43 Emphysema
 - J43.0 MacLeod's syndrome
 - J43.1 Panlobular emphysema
 - J43.2 Centrilobular emphysema
 - J43.8 Other emphysema
 - J43.9 Emphysema, unspecified
- J44 Other chronic obstructive pulmonary disease
 - J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection
 - J44.1 Chronic obstructive pulmonary disease with acute exacerbation, unspecified
 - J44.8 Other specified chronic obstructive pulmonary disease
 - J44.9 Chronic obstructive pulmonary disease, unspecified

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CORONARY ARTERY DISEASE

Glossary:


- *β-receptor antagonist* – Beta-receptor antagonist

Applicable ICD 10 Coding:

- I20 Angina pectoris
 - I20.0 Unstable angina
 - I20.1 Angina pectoris with documented spasm
 - I20.8 Other forms of angina pectoris
 - I20.9 Angina pectoris, unspecified
- I25 Chronic ischaemic heart disease
 - I25.0 Atherosclerotic cardiovascular disease, so described
 - I25.1 Atherosclerotic heart disease
 - I25.2 Old myocardial infarction
 - I25.3 Aneurysm of heart
 - I25.4 Coronary artery aneurysm
 - I25.5 Ischaemic cardiomyopathy
 - I25.6 Silent myocardial ischaemia
 - I25.8 Other forms of chronic ischaemic heart disease
 - I25.9 Chronic ischaemic heart disease, unspecified

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

CROHN'S DISEASE

Glossary:


- 5-ASA – 5-Aminosalicylic acid
- IV – Intravenous

Applicable ICD 10 Coding:

- K50 Crohn's disease [regional enteritis]
 - K50.0 Crohn's disease of small intestine
 - K50.1 Crohn's disease of large intestine
 - K50.8 Other Crohn's disease
 - K50.9 Crohn's disease, unspecified

Note:

- 4. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 1. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 2. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**


DIABETES INSIPIDUS

Applicable ICD 10 Coding:

- E 23.2 Diabetes insipidus

Note:

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
 - a. not be inconsistent with this algorithm;
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

DIABETES MELLITUS TYPE 1**Glossary:**

- HbA1c – Glycosylated hemoglobin

Applicable ICD 10 Coding:


- E10 Insulin-dependent diabetes mellitus
 - E10.0 Insulin-dependent diabetes mellitus with coma
 - E10.1 Insulin-dependent diabetes mellitus with ketoacidosis
 - E10.2 Insulin-dependent diabetes mellitus with renal complications
 - E10.3 Insulin-dependent diabetes mellitus with ophthalmic complications
 - E10.4 Insulin-dependent diabetes mellitus with neurological complications
 - E10.5 Insulin-dependent diabetes mellitus with peripheral circulatory complications
 - E10.6 Insulin-dependent diabetes mellitus with other specified complications
 - E10.7 Insulin-dependent diabetes mellitus with multiple complications
 - E10.8 Insulin-dependent diabetes mellitus with unspecified complications
 - E10.9 Insulin-dependent diabetes mellitus without complications


Applicable ICD 10 Coding: (continued)

- **E12 Malnutrition-related diabetes mellitus**
 - E12.0 Malnutrition-related diabetes mellitus with coma
 - E12.1 Malnutrition-related diabetes mellitus with ketoacidosis
 - E12.2 Malnutrition-related diabetes mellitus with renal complications
 - E12.3 Malnutrition-related diabetes mellitus with ophthalmic complications
 - E12.4 Malnutrition-related diabetes mellitus with neurological complications
 - E12.5 Malnutrition-related diabetes mellitus with peripheral circulatory complications
 - E12.6 Malnutrition-related diabetes mellitus with other specified complications
 - E12.7 Malnutrition-related diabetes mellitus with multiple complications
 - E12.8 Malnutrition-related diabetes mellitus with unspecified complications
 - E12.9 Malnutrition-related diabetes mellitus without complications
- **O24 Diabetes mellitus in pregnancy**
 - O24.0 Pre-existing diabetes mellitus, insulin-dependent
 - O24.2 Pre-existing malnutrition-related diabetes mellitus
 - O24.3 Pre-existing diabetes mellitus, unspecified

Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

DIABETES MELLITUS TYPE 2



Glossary:

- HbA1c – Glycosylated hemoglobin
- BMI – Body mass index

Applicable ICD 10 Coding:


- E11 Non-insulin-dependent diabetes mellitus
 - E11.0 Non-insulin-dependent diabetes mellitus with coma
 - E11.1 Non-insulin-dependent diabetes mellitus with ketoacidosis
 - E11.2 Non-insulin-dependent diabetes mellitus with renal complications
 - E11.3 Non-insulin-dependent diabetes mellitus with ophthalmic complications
 - E11.4 Non-insulin-dependent diabetes mellitus with neurological complications
 - E11.5 Non-insulin-dependent diabetes mellitus with peripheral circulatory complications
 - E11.6 Non-insulin-dependent diabetes mellitus with other specified complications
 - E11.7 Non-insulin-dependent diabetes mellitus with multiple complications
 - E11.8 Non-insulin-dependent diabetes mellitus with unspecified complications
 - E11.9 Non-insulin-dependent diabetes mellitus without complications


Applicable ICD 10 Coding: (continued)

- **E12 Malnutrition-related diabetes mellitus**
 - E12.0 Malnutrition-related diabetes mellitus with coma
 - E12.1 Malnutrition-related diabetes mellitus with ketoacidosis
 - E12.2 Malnutrition-related diabetes mellitus with renal complications
 - E12.3 Malnutrition-related diabetes mellitus with ophthalmic complications
 - E12.4 Malnutrition-related diabetes mellitus with neurological complications
 - E12.5 Malnutrition-related diabetes mellitus with peripheral circulatory complications
 - E12.6 Malnutrition-related diabetes mellitus with other specified complications
 - E12.7 Malnutrition-related diabetes mellitus with multiple complications
 - E12.8 Malnutrition-related diabetes mellitus with unspecified complications
 - E12.9 Malnutrition-related diabetes mellitus without complications
- **O24 Diabetes mellitus in pregnancy**
 - O24.1 Pre-existing diabetes mellitus, non-insulin-dependent
 - O24.2 Pre-existing malnutrition-related diabetes mellitus
 - O24.3 Pre-existing diabetes mellitus, unspecified


Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

DYSRHYTHMIAS**Chronic Atrial Fibrillation**

Chronic Atrial Flutter

Ventricular Tachycardia



Glossary:


- INR – International normalized ratio
- *β-blocker* – Beta-receptor blocker
- AV node – Atrioventricular node
- LV – Left ventricular

Applicable ICD 10 Coding:

- I47.2 Ventricular tachycardia
- I48 Atrial fibrillation and flutter

Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**


EPILEPSY

Applicable ICD 10 Coding:

- G40 Epilepsy
 - G40.0 Localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset
 - G40.1 Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
 - G40.2 Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
 - G40.3 Generalized idiopathic epilepsy and epileptic syndromes
 - G40.4 Other generalized epilepsy and epileptic syndromes
 - G40.5 Special epileptic syndromes
 - G40.6 Grand mal seizures, unspecified (with or without petit mal)
 - G40.7 Petit mal, unspecified, without grand mal seizures
 - G40.8 Other epilepsy
 - G40.9 Epilepsy, unspecified
- G41 Status epilepticus
 - G41.0 Grand mal status epilepticus
 - G41.1 Petit mal status epilepticus
 - G41.2 Complex partial status epilepticus
 - G41.8 Other status epilepticus
 - G41.9 Status epilepticus, unspecified

Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

GLAUCOMA

Glossary:


- β -blocker – Beta-receptor blocker
- α_2 -agonist – Alpha-2 receptor agonist


Applicable ICD 10 Coding:

- H40 Glaucoma
 - H40.0 Glaucoma suspect
 - H40.1 Primary open-angle glaucoma
 - H40.2 Primary angle-closure glaucoma
 - H40.3 Glaucoma secondary to eye trauma
 - H40.4 Glaucoma secondary to eye inflammation
 - H40.5 Glaucoma secondary to other eye disorders
 - H40.6 Glaucoma secondary to drugs
 - H40.8 Other glaucoma
 - H40.9 Glaucoma, unspecified
- Q15.0 Congenital glaucoma

Note:

1. **Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
2. **To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. **not be inconsistent with this algorithm;**
 - b. **be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. **comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
3. **This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

HAEMOPHILIA**Haemophilia A**

**Glossary:**


- Factor VIII – Factor eight
- Factor IX – Factor nine
- NSAIDs – Non-steroidal anti-inflammatory agents


Applicable ICD 10 Coding:

- D66 Hereditary factor VIII deficiency
- D67 Hereditary factor IX deficiency

Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

HYPERLIPIDAEMIA

**Glossary:**


- TC – Total cholesterol
- TG – Triglycerides
- HDLC – High density lipoproteins cholesterol
- LDLC – Low density lipoproteins cholesterol
- MI – Myocardial infarct

Applicable ICD 10 Coding:

- E78.0 Pure hypercholesterolaemia
- E78.1 Pure hyperglyceridaemia
- E78.2 Mixed hyperlipidaemia
- E78.3 Hyperchylomicronaemia
- E78.4 Other hyperlipidaemia
- E78.5 Hyperlipidaemia, unspecified

Note:

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
 - a. not be inconsistent with this algorithm;**
 - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
 - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

HYPERTENSION

-
- ```
graph TD; A[Start with low dose and titrate if necessary] --> B[Goal BP not achieved: <140/90 mmHg in uncomplicated cases, <135/85mmHg in diabetes]; B --> C[No response or adverse event]; B --> D[Inadequate response but drug tolerated]; C --> E[Substitute another drug from different class]; D --> F[Add second agent from different class (especially diuretic if not already used)]; E --> G[Goal BP not achieved]; F --> G; G --> H[Add agent from different class or review];
```
- Angina:  $\beta$ -blocker, CCB
  - Prior myocardial infarct or CAD:  $\beta$ -blocker and ACE inhibitor
  - Post MI:  $\beta$ -blocker or ACE inhibitor (in patients with systolic dysfunction)
  - Heart Failure: ACE inhibitor,  $\beta$ -blocker, diuretics (furosemide or spironolactone)
  - Left ventricular hypertrophy: ACE inhibitor
  - Stroke: Low dose diuretic, ACE inhibitor
  - Type 1 Diabetes with proteinuria: ACE inhibitor, usually in combination with diuretic
  - Type 2 Diabetes with microalbuminuria: ACE inhibitor or ARB, usually in combination with diuretic
  - Type 2 Diabetes without proteinuria: ACE inhibitor, usually in combination with a diuretic
  - Type 2 Diabetes with proteinuria: ACE inhibitor or ARB usually in combination with diuretic
  - Isolated systolic hypertension (elderly): diuretic preferred (low dose thiazides), long-acting CCB
  - Prostatism:  $\alpha$ -blocker (this should not be used as monotherapy)

Start with low dose  
and titrate if necessary

Goal BP not achieved:  
<140/90 mmHg in uncomplicated cases,  
<135/85mmHg in diabetes

No response  
or adverse  
event

Inadequate  
response but  
drug tolerated

Substitute another  
drug from different  
class

Add second agent from  
different class (especially  
diuretic if not already used)

Goal BP not achieved

Add agent from different class or review

**Glossary:**


- *$\alpha$ -blocker* – Alpha-receptor blocker
- *ACE inhibitor* – Angiotensin converting enzyme inhibitor
- *ARB* – Angiotensin receptor blocker
- *BP* – Blood pressure
- *$\beta$ -blocker* – Beta-receptor blocker
- *CCB* – Calcium channel blocker
- *CCF* – Chronic / Congestive cardiac failure
- *CAD* – Coronary artery disease
- *LV* – Left ventricular
- *MI* – Myocardial infarct

**Applicable ICD 10 Coding:**

- I10 Essential (primary) hypertension
- I11 Hypertensive heart disease
  - I11.0 Hypertensive heart disease with (congestive) heart failure
  - I11.9 Hypertensive heart disease without (congestive) heart failure
- I12 Hypertensive renal disease
  - I12.0 Hypertensive renal disease with renal failure
  - I12.9 Hypertensive renal disease without renal failure
- I13 Hypertensive heart and renal disease
  - I13.0 Hypertensive heart and renal disease with (congestive) heart failure
  - I13.1 Hypertensive heart and renal disease with renal failure
  - I13.2 Hypertensive heart and renal disease with both (congestive) heart failure and renal failure
  - I13.9 Hypertensive heart and renal disease, unspecified
- I15 Secondary hypertension
  - I15.0 Renovascular hypertension
  - I15.1 Hypertension secondary to other renal disorders
  - I15.2 Hypertension secondary to endocrine disorders
  - I15.8 Other secondary hypertension
  - I15.9 Secondary hypertension, unspecified
- O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium
  - O10.0 Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium
  - O10.1 Pre-existing hypertensive heart disease complicating pregnancy, childbirth and the puerperium
  - O10.2 Pre-existing hypertensive renal disease complicating pregnancy, childbirth and the puerperium
  - O10.3 Pre-existing hypertensive heart and renal disease complicating pregnancy, childbirth and the puerperium
  - O10.4 Pre-existing secondary hypertension complicating pregnancy, childbirth and the puerperium
  - O10.9 Unspecified pre-existing hypertension complicating pregnancy, childbirth and the puerperium
- O11 Pre-existing hypertensive disorder with superimposed proteinuria

**Note:**

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
  - a. not be inconsistent with this algorithm;
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

**HYPOTHYROIDISM****Glossary:**

- TSH – Thyroid stimulating hormone
- FT4 – Free thyroxine

**Applicable ICD 10 Coding:**


- E01.8 Other iodine-deficiency-related thyroid disorders and allied conditions
- E02 Subclinical iodine-deficiency hypothyroidism

**Applicable ICD 10 Coding: (continued)**

- E03 Other hypothyroidism
  - E03.0 Congenital hypothyroidism with diffuse goitre
  - E03.1 Congenital hypothyroidism without goitre
  - E03.2 Hypothyroidism due to medicaments and other exogenous substances
  - E03.3 Postinfectious hypothyroidism
  - E03.4 Atrophy of thyroid (acquired)
  - E03.5 Myxoedema coma
  - E03.8 Other specified hypothyroidism
  - E03.9 Hypothyroidism, unspecified
- E89.0 Postprocedural hypothyroidism

**Note:**

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
  - a. not be inconsistent with this algorithm;
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

**MULTIPLE SCLEROSIS****Glossary:**

- IV – Intravenous


**Applicable ICD 10 Coding:**

- G35 Multiple sclerosis



**Note:**

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
  - a. not be inconsistent with this algorithm;**
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**




Applicable ICD 10 Coding:

- G20 Parkinson's disease
- G21 Secondary parkinsonism
  - G21.0 Malignant neuroleptic syndrome
  - G21.1 Other drug-induced secondary parkinsonism
  - G21.2 Secondary parkinsonism due to other external agents
  - G21.3 Postencephalitic parkinsonism
  - G21.8 Other secondary parkinsonism
  - G21.9 Secondary parkinsonism, unspecified

**Note:**

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
  - a. not be inconsistent with this algorithm;**
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

**RHEUMATOID ARTHRITIS**

**Glossary:**


- **DMARD** – Disease modifying antirheumatic drugs
- **NSAID** – Non-steroidal anti-inflammatory agents

**Applicable ICD 10 Coding:**

- **M05 Seropositive rheumatoid arthritis**
  - M05.0 Felty's syndrome
  - M05.1 Rheumatoid lung disease (J99.0\*)
  - M05.2 Rheumatoid vasculitis
  - M05.3 Rheumatoid arthritis with involvement of other organs and systems
  - M05.8 Other seropositive rheumatoid arthritis
  - M05.9 Seropositive rheumatoid arthritis, unspecified
- **M06 Other rheumatoid arthritis**
  - M06.0 Seronegative rheumatoid arthritis
  - M06.1 Adult-onset Still's disease
  - M06.2 Rheumatoid bursitis
  - M06.3 Rheumatoid nodule
  - M06.4 Inflammatory polyarthropathy
  - M06.8 Other specified rheumatoid arthritis
  - M06.9 Rheumatoid arthritis, unspecified
- **M08.0 Juvenile rheumatoid arthritis**

**Note:**

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
  - a. not be inconsistent with this algorithm;**
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

**SCHIZOPHRENIA**

**Glossary:**


- ECT – Electroconvulsive therapy

**Applicable ICD 10 Coding:**

- F20 Schizophrenia
  - F20.0 Paranoid schizophrenia
  - F20.1 Hebephrenic schizophrenia
  - F20.2 Catatonic schizophrenia
  - F20.3 Undifferentiated schizophrenia
  - F20.4 Post-schizophrenic depression
  - F20.5 Residual schizophrenia
  - F20.6 Simple schizophrenia
  - F20.8 Other schizophrenia
  - F20.9 Schizophrenia, unspecified

**Note:**

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
  - a. not be inconsistent with this algorithm;
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.

**SYSTEMIC LUPUS ERYTHEMATOSUS**



**Glossary:**


- IV – Intravenous
- NSAIDs – Non-steroidal anti-inflammatory agents
- SLE – Systemic lupus erythematosus

**Applicable ICD 10 Coding:**

- M32 Systemic lupus erythematosus
  - M32.0 Drug-induced systemic lupus erythematosus
  - M32.1 Systemic lupus erythematosus with organ or system involvement
  - M32.8 Other forms of systemic lupus erythematosus
  - M32.9 Systemic lupus erythematosus, unspecified
- L93 Lupus erythematosus
  - L93.0 Discoid lupus erythematosus
  - L93.1 Subacute cutaneous lupus erythematosus
  - L93.2 Other local lupus erythematosus

**Note:**

- 1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.**
- 2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –**
  - a. not be inconsistent with this algorithm;**
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and**
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998**
- 3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.**

**ULCERATIVE COLITIS**

**Glossary:**

- 5-ASA – 5-Aminosalicylic acid
- IV – Intravenous

**Applicable ICD 10 Coding:**

- K51 Ulcerative colitis
  - K51.0 Ulcerative (chronic) enterocolitis
  - K51.1 Ulcerative (chronic) ileocolitis
  - K51.2 Ulcerative (chronic) proctitis
  - K51.3 Ulcerative (chronic) rectosigmoiditis
  - K51.4 Pseudopolyposis of colon
  - K51.5 Mucosal proctocolitis
  - K51.8 Other ulcerative colitis
  - K51.9 Ulcerative colitis, unspecified

**Note:**

1. Medical management reasonably necessary for the delivery of treatment described in this algorithm is included within this benefit, subject to the application of managed health care interventions by the relevant medical scheme.
2. To the extent that a medical scheme applies managed health care interventions in respect of this benefit, for example clinical protocols for diagnostic procedures or medical management, such interventions must –
  - a. not be inconsistent with this algorithm;
  - b. be developed on the basis of evidence-based medicine, taking into account considerations of cost-effectiveness and affordability; and
  - c. comply with all other applicable regulations made in terms of the Medical Schemes Act, 131 of 1998
3. This algorithm may not necessarily always be clinically appropriate for the treatment of children. If this is the case, alternative paediatric clinical management is included within this benefit if it is supported by evidence-based medicine, taking into account considerations of cost-effectiveness and affordability.